Treating Autism: full recording of EU AIMS dialogue October 2014

What would it mean to develop medical treatment for the core features of autism? Recent research has enriched our understanding of the biology of autism, as well as the social experiences of being autistic, but the core biological features of autism are still not well understood. Any medication for the core symptoms of autism is thus still some way off in the future. Nonetheless, much research is now looking for biological markers for which treatments might be developed. ‘EU-AIMS’ is a collaboration seeking new methods for the development of biological markers and drug treatments for autism. There is considerable support for such an endeavour, including from groups representing autistic people, and their families and allies. However, other autistic people, some autism self-advocacy groups, and some ethical and legal scholars, are concerned about autism coming to be defined only as a biological disorder in need of treatment – and have called for wide debate on the relationships between biology, treatment, and difference in autism. This public dialogue, organised by the Ethics Advisory Board of EU-AIMS, brings together autism advocates and self-advocates, psychiatrists, and ethicists, to discuss these issues.  Treating Autism: full recording of EU AIMS dialogue October 2014 An edited version of the even can be found here.